Friday

28th Apr 2017

Opinion

Why are our medicines so expensive?

  • 'Austerity politics mean people in Europe are also facing a growing treatment access gap' (Photo: isobrown)

In the lead-up to an inter ministerial meeting between EU and India next week, European trade negotiators continue to pressure India and other developing countries to accept so-called “free trade” agreements that favour patent monopolies, high medicines prices, and the interests of the pharmaceutical industry.

Instead, the EU should be promoting open innovation and should work to bring down the prices of essential medicines, both abroad and within its borders.

Dear EUobserver reader

Subscribe now for unrestricted access to EUobserver.

Sign up for 30 days' free trial, no obligation. Full subscription only 15 € / month or 150 € / year.

  1. Unlimited access on desktop and mobile
  2. All premium articles, analysis, commentary and investigations
  3. EUobserver archives

EUobserver is the only independent news media covering EU affairs in Brussels and all 28 member states.

♡ We value your support.

If you already have an account click here to login.

For Europeans who have never had to worry about access to health care or medicines, it comes as a shock that the downward spiral of financial crisis and ensuing austerity politics have put at risk our once sacrosanct right to access affordable, quality health care.

Reading the agonizing stories of cancer patients in Greece who can no longer afford the medicines that keep them alive, or immigrants in Spain who no longer get costly AIDS cocktails because their health care is being revoked, it is clear we have our priorities wrong.

But why are our medicines so expensive?

For decades, Western countries have relied on an innovation model that provides generous incentives to pharmaceutical companies to develop and test medicines. Public funds support much of the early research for new medicines, and companies that bring new drugs to market receive tax credits and patents that let them charge monopoly prices and make high profits.

For a long time, wealthy countries with comprehensive health insurance coverage considered expensive medicines an acceptable price to pay for medical innovation and a booming pharmaceutical sector, since no one had to pay the full cost of medicines out-of-pocket.

Now that austerity measures are shifting these high cost to patients, however, we must ask - what is the point of having medical innovation if we cannot afford the therapies it delivers?

This, of course, is the situation that people living in low and middle income countries have confronted all along. For example, the price of life-saving hepatitis C medicines, sold under monopoly pricing by Merck and Roche can easily cost €15,000 per treatment.

Similarly, Novartis has maintained a global price of around €2,000 per month for its breakthrough cancer drug Glivec.

Treatment access gap

It is no surprise that virtually no one outside of rich countries can access these medicines. Now, austerity politics in the EU mean that poor, unemployed, and otherwise disadvantaged groups in Europe are also facing a growing treatment access gap.

We know from other countries that most medicines can be produced at a fraction of the price they cost in Europe. For instance, a generic version of Glivec is available in India at around €120 per month, much to the discontent of Novartis, who challenged India’s patent law in court to maintain its grip on profits.

Last week, after a seven year legal battle, patients won a landmark victory when India’s Supreme Court upheld the legality of the generic, thus safeguarding India’s role as a global hub for generic medicines.

Yet instead of finding ways to reduce the price of medicines, the European Commission’ is pursuing deals that would further restrict countries’ abilities to speed up generic availability and effective price competition. Following what Commissioner Karel De Gucht calls an “ambitious European free trade agenda”, they seek to promote the exportation of Europe's pharmaceutical products at high prices, favouring pharma companies over the health of the people.

EU India trade talks

In protracted closed door negotiations for an EU-India Free Trade Agreement, the Directorate General for Trade and corporate advisors continue to pressure India to accept provisions that undermine public health safeguards and favour corporate interests.

These include enhanced protection of patents and clinical data, which are known to delay entry of generic medicines into the market. Patients and health activists in countries such as Jordan and Guatemala have learnt the hard way that access to medicines is among the first issues to be compromised in such trade negotiations, seeing medicines prices soar once the agreements were signed.

In effect, the EU is pressuring India to make concessions that will undermine the health of millions of people worldwide, for whom India is their affordable pharmacy.

Rather than exporting its unsustainable model of patent-driven innovation and expensive medicines, Europe should stay focused on one of its greatest traditions - accessible health care for all.

While it could learn lessons from India about reducing medicine prices, Europe is ideally positioned to lead the way towards novel, open, and collaborative models of medical innovation that will ensure new medicines meet our health needs at prices people can afford.

We know this is possible. Even the head of GlaxoSmithKline Andrew Witty admits that the alleged $1 billion price tag for drug development - the chief excuse for high medicines prices - is “one of the great myths of the industry.”

In this age of financial difficulties, expensive medicines need not be.

The writer is the director of the Open Society Public Health Programme’s Access to Essential Medicines Initiative.

Focus

EU alternative-medicine safety rules will slim down access

Measures forcing the purveyors of alternative medicines to prove they are safe and that they have a long track-record of people believing they work will cut the number of herbal remedies and traditional Chinese medical products on the European market from 1 May.

Thousands march in India against EU trade deal

Thousands of HIV-positive protesters took to the streets in downtown New Delhi on Wednesday, concerned that an imminent EU-India free trade agreement will end the production of affordable life-prolonging drugs.

Column / Brexit Briefing

May's drive for one-party Brexit state

Snap election will kill off attempts to reopen debate on second referendum and inflict further damaged on confused opposition.

News in Brief

  1. Vote of no confidence prepared against Spanish PM
  2. Syria to buy Russian anti-missile system
  3. Germany seeks partial burka ban
  4. Libya has no plan to stop migration flows
  5. EU has no evidence of NGO-smuggler collusion in Libya
  6. Poland gets 'final warning' on logging in ancient forest
  7. Commission gives Italy final warning on air pollution
  8. Romania and Slovenia taken to court over environment policies

Stakeholders' Highlights

  1. ECR GroupSyed Kamall: We Need a New, More Honest Relationship With Turkey
  2. Counter BalanceParliament Sends Strong Signal to the EIB: Time to Act on Climate Change
  3. ACCARisks and Opportunities of Blockchain and Shared Ledgers Technologies in Financial Services
  4. UNICEFRace Against Time to Save Millions of Lives in Yemen
  5. Nordic Council of MinistersDeveloping Independent Russian-Language Media in the Baltic Countries
  6. Swedish EnterprisesReform of the European Electricity Market: Lessons from the Nordics, Brussels 2 May
  7. Malta EU 2017Green Light Given for New EU Regulation to Bolster External Border Checks
  8. Counter BalanceCall for EU Commission to Withdraw Support of Trans-Adriatic Pipeline
  9. ACCAEconomic Confidence at Highest Since 2015
  10. European Federation of Allergy and Airways60%-90% of Your Life Is Spent Indoors. How Does Poor Indoor Air Quality Affect You?
  11. European Gaming and Betting AssociationCJEU Confirms Obligation for a Transparent Licensing Process
  12. Nordic Council of MinistersNordic Region and the US: A Time of Warlike Rhetoric and Militarisation?

Stakeholders' Highlights

  1. European Free AllianceEFA MEPs Vote in Favor of European Parliament's Brexit Mandate
  2. Mission of China to the EUXinhua Insight: China to Open up Like Never Before
  3. World VisionViolence Becomes New Normal for Syrian Children
  4. International Partnership for Human RightsTime to Turn the Tide and End Repression of Central Asia's Civil Society
  5. European Free AllianceAutonomia to Normalnosc - Poland Urged to Re-Grant Autonomy to Silesia
  6. UNICEFHitting Rock Bottom - How 2016 Became the Worst Year for #ChildrenofSyria
  7. Malta EU 2017Green Light Given for New EU Regulation to Bolster External Border Checks
  8. ACCAG20 Citizens Want 'Big Picture' Tax Policymaking, According to Global Survey
  9. Belgrade Security ForumCall for Papers: European Union as a Global Crisis Manager - Deadline 30 April
  10. European Gaming & Betting Association60 Years Rome Treaty – 60 Years Building an Internal Market
  11. Malta EU 2017New EU Rules to Prevent Terrorism and Give More Rights to Victims Approved
  12. European Jewish Congress"Extremists Still Have Ability and Motivation to Murder in Europe" Says EJC President